Here are four things to know:
1. The shares were sold at an average of $24 per share, for a total transaction value of $841,050.
2. Currently, Mr. Phalen owns a total of 91,733 shares.
3. Out of 18 analysts covering Boston Scientific, 14 rate it a “buy,” zero rate it “sell,” while four rate it “hold.”
4. The company has a market cap of $33.15 billion.
More articles on GI/endoscopy:
Surveillance endoscopy improves esophageal cancer outcomes in Barrett’s esophagus patients: 3 insights
Small bowel resection inpatient costs total $28.5k & 7 more statistics
Dr. Maxime Mahe wins 2016 AGA-Athena Troxel Blackburn Award: 4 notes
